These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 27093164)

  • 1. Long-term Serologic Follow-up of Children Vaccinated with a Pediatric Formulation of Virosomal Hepatitis A Vaccine Administered With Routine Childhood Vaccines at 12-15 Months of Age.
    Dagan R; Ashkenazi S; Livni G; Go O; Bagchi P; Sarnecki M
    Pediatr Infect Dis J; 2016 Jul; 35(7):e220-8. PubMed ID: 27093164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concomitant administration of a virosome-adjuvanted hepatitis a vaccine with routine childhood vaccines at age twelve to fifteen months: a randomized controlled trial.
    Dagan R; Amir J; Livni G; Greenberg D; Abu-Abed J; Guy L; Ashkenazi S; Foresner G; Tewald F; Schätzl HM; Hoffmann D; Ibanez R; Herzog C
    Pediatr Infect Dis J; 2007 Sep; 26(9):787-93. PubMed ID: 17721372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and tolerability of a paediatric presentation of a virosomal hepatitis A vaccine in Chilean children aged 1-16 years.
    Abarca K; Ibáñez I; de la Fuente P; Cerda L; Bergeret J; Frösner G; Ibarra H
    Vaccine; 2011 Nov; 29(48):8855-62. PubMed ID: 21983354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term antibody persistence in children after vaccination with the pediatric formulation of an aluminum-free virosomal hepatitis A vaccine.
    Van Herck K; Hens A; De Coster I; Vertruyen A; Tolboom J; Sarnecki M; Van Damme P
    Pediatr Infect Dis J; 2015 Apr; 34(4):e85-91. PubMed ID: 25389920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of booster vaccination with a virosomal hepatitis A vaccine after primary immunization with an aluminum-adsorbed hepatitis A vaccine.
    Beck BR; Hatz CF; Loutan L; Steffen R
    J Travel Med; 2004; 11(4):201-6. PubMed ID: 15541221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of a pediatric dose of a virosomal hepatitis A vaccine in healthy children in India.
    Jain H; Kumavat V; Singh T; Versteilen A; Sarnecki M
    Hum Vaccin Immunother; 2014; 10(7):2089-97. PubMed ID: 25424821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity, safety, and interchangeability of two inactivated hepatitis A vaccines in Chilean children.
    Abarca K; Ibánez I; Perret C; Vial P; Zinsou JA
    Int J Infect Dis; 2008 May; 12(3):270-7. PubMed ID: 17988917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of a pediatric dose of a virosome-adjuvanted hepatitis A vaccine: a controlled trial in children aged 1-16 years.
    Van Der Wielen M; Vertruyen A; Froesner G; Ibáñez R; Hunt M; Herzog C; Van Damme P
    Pediatr Infect Dis J; 2007 Aug; 26(8):705-10. PubMed ID: 17848882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid antibody response after vaccination with a virosomal hepatitis a vaccine.
    Ambrosch F; Finkel B; Herzog C; Koren A; Kollaritsch H
    Infection; 2004 Jun; 32(3):149-52. PubMed ID: 15188074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of a pediatric dose virosomal hepatitis A vaccine in Thai HIV-infected children.
    Saksawad R; Likitnukul S; Warachit B; Hanvivatvong O; Poovorawan Y; Puripokai P
    Vaccine; 2011 Jun; 29(29-30):4735-8. PubMed ID: 21570433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly.
    D'Acremont V; Herzog C; Genton B
    J Travel Med; 2006; 13(2):78-83. PubMed ID: 16553593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of immunogenicity and persistence between inactivated hepatitis A vaccine Healive® and Havrix® among children: A 5-year follow-up study.
    Yu C; Song Y; Qi Y; Li C; Jiang Z; Li C; Zhang W; Wang L; Xia J
    Hum Vaccin Immunother; 2016 Oct; 12(10):2595-2602. PubMed ID: 27385349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interchangeability and tolerability of a virosomal and an aluminum-adsorbed hepatitis A vaccine.
    Bovier PA; Farinelli T; Loutan L
    Vaccine; 2005 Mar; 23(19):2424-9. PubMed ID: 15752828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of an inactivated hepatitis A pediatric vaccine: three-year post-booster follow-up.
    Dagan R; Greenberg D; Weber F
    Vaccine; 2005 Oct; 23(44):5144-8. PubMed ID: 16043271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicted 30-year protection after vaccination with an aluminum-free virosomal hepatitis A vaccine.
    Bovier PA; Bock J; Ebengo TF; Frösner G; Glaus J; Herzog C; Loutan L
    J Med Virol; 2010 Oct; 82(10):1629-34. PubMed ID: 20827757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the safety and immunogenicity of live attenuated and inactivated hepatitis A vaccine in healthy Chinese children aged 18 months to 16 years: results from a randomized, parallel controlled, phase IV study.
    Ma F; Yang J; Kang G; Sun Q; Lu P; Zhao Y; Wang Z; Luo J; Wang Z
    Clin Microbiol Infect; 2016 Sep; 22(9):811.e9-811.e15. PubMed ID: 27345175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of an inactivated hepatitis A vaccine when coadministered with Diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines in children 15 months of age.
    Trofa AF; Klein NP; Paul IM; Michaels MG; Goessler M; Chandrasekaran V; Blatter M
    Pediatr Infect Dis J; 2011 Sep; 30(9):e164-9. PubMed ID: 21494175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of virosome hepatitis A vaccine in young children in Nicaragua: randomized placebo-controlled trial.
    Mayorga Pérez O; Herzog C; Zellmeyer M; Loáisiga A; Frösner G; Egger M
    J Infect Dis; 2003 Sep; 188(5):671-7. PubMed ID: 12934183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open, prospective, randomized study comparing the immunogenicity and safety of two inactivated hepatitis A pediatric vaccines in toddlers, children and adolescents in China.
    Li RC; Li Y; Yi N; Huang L; Wan Z; Zhang Y; Rasuli A
    Pediatr Infect Dis J; 2013 Feb; 32(2):e77-81. PubMed ID: 23334341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epaxal: a virosomal vaccine to prevent hepatitis A infection.
    Bovier PA
    Expert Rev Vaccines; 2008 Oct; 7(8):1141-50. PubMed ID: 18844588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.